South Africa
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 53 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 25 (15–38) 48 (28–73)
Mortality (HIV+TB only) 64 (47–83) 121 (90–158)
Prevalence  (includes HIV+TB) 380 (210–590) 715 (396–1 126)
Incidence  (includes HIV+TB) 450 (410–520) 860 (776–980)
Incidence (HIV+TB only) 270 (240–310) 520 (464–594)
Case detection, all forms (%) 69 (60–76)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.8 (1.4–2.3) 6.7 (5.4–8.2)
MDR-TB cases among notified pulmonary
TB cases
4 600 (3 600–5 900) 2 200 (1 800–2 700)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 109 630   7 751
Pulmonary, clinically diagnosed 148 658   8 627
Extrapulmonary 37 709   5
       
Total new and relapse 312 380    
Previously treated, excluding relapses 16 516    
Total cases notified 328 896    
Among 312 380 new and relapse cases:
36 671 (12%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB     258 401
Laboratory-confirmed RR-/MDR-TB cases     26 023
Patients started on MDR-TB treatment     10 663
TB/HIV 2013 Number (%)
TB patients with known HIV status 294 504 (90)
HIV-positive TB patients 181 736 (62)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 146 973 (81)
HIV-positive TB patients on antiretroviral therapy (ART) 120 298 (66)
HIV-positive people screened for TB 961 967  
HIV-positive people provided with IPT 339 518  
Treatment success rate (%)
New and relapse cases registered in 2012 77
Previously treated cases, excluding relapse, registered in 2012 64
HIV-positive TB cases, all types, registered in 2012 74
RR-/MDR-TB cases started on second-line treatment in 2011 45
XDR-TB cases started on second-line treatment in 2011 15
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.4
Drug susceptibility testing (per 5 million population) 1.4
Sites performing Xpert MTB/RIF 207
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 162
% Funded domestically 84%
% Funded internationally 16%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-31 Data: www.who.int/tb/data